TY - JOUR
T1 - Positive Affect and Well-Being in Huntington's Disease Moderates the Association between Functional Impairment and HRQOL Outcomes
AU - Ready, Rebecca E.
AU - Boileau, Nicholas R.
AU - Barton, Stacey K.
AU - Lai, Jin Shei
AU - McCormack, Michael K.
AU - Cella, David
AU - Fritz, Nora E.
AU - Paulsen, Jane S.
AU - Carlozzi, Noelle E.
N1 - Funding Information:
Drs. Ready, Boileau, Barton, Cella, and Fritz have no conflicts of interest to report. J.-S. Lai currently has research grants from the NIH; she declares no conflicts of interest. M.K. McCormack, M.K. currently has grants from the NJ Department of Health; he has no conflicts of interest to report. J.S. Paulsen currently has research grants funded by NIH and CHDI; she consults for CHDI, Stryker, and Wave Life Sciences. Dr. Paulsen has no conflicts of interest to report. N.E. Carlozzi is supported by grant funding from the NIH, Neilsen Foundation, Department of Defense, CHDI, and Goldfinch, LLC, as well as a contract from the Centers for Medicare & Medicaide Services (CMMS); she has served as a measurement consultant for Teva Pharmaceuticals. Dr. Carlozzi has no conflicts of interest to report.
Funding Information:
Work on this manuscript was supported by the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (R01NS077946) and the National Center for Advancing Translational Sciences (UL1TR000433). In addition, a portion of this study sample was collected in conjunction with the Predict-HD study. The Predict-HD study was supported by the NIH, National Institute of Neurological Disorders and Stroke (R01NS040068),Center for Inherited Disease Research (provided supported for sample phenotyping), and the CHDI Foundation (award to the University of Iowa).
Publisher Copyright:
© 2019-IOS Press and the authors. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background: Positive affect is associated with resiliency and beneficial health outcomes, but little is known about associations between positive affect and health-related quality of life (HRQOL) in Huntington's disease (HD). Objective: This longitudinal study determined the association between positive affect and several HRQOL outcomes in persons with HD. Functional status was examined as a moderator of the association between positive affect and HRQOL. Methods: Participants, with premanifest (i.e., genetically at risk but no clinical diagnosis, n = 50) and manifest HD (earlystage n = 171; late-stage n = 101), completed a measure of positive affect and well-being and several HRQOL measures at baseline, 12-, and 24-month follow-ups. UHDRS Functional Assessment scale indicated functional status. Results: Positive affect was associated with better HRQOL for persons with premanifest and manifest HD over the 24-month time frame. These associations were moderated by functional status. For persons with higher functional status, positive affect was associated with better HRQOL, including less depression, lower anxiety, less anger, better social role satisfaction, better executive functions, greater upper extremity function, less dyscontrol, and less concern with death and dying. For persons with lower functional status, positive affect was not associated with HRQOL. Conclusions: Positive affect predicted better self-reported HRQOL over a 24-month period in persons with premanifest and manifest HD, particularly when participnats had better functional status. Interventions to enhance positive affect in HD may have beneficial effects on HRQOL.
AB - Background: Positive affect is associated with resiliency and beneficial health outcomes, but little is known about associations between positive affect and health-related quality of life (HRQOL) in Huntington's disease (HD). Objective: This longitudinal study determined the association between positive affect and several HRQOL outcomes in persons with HD. Functional status was examined as a moderator of the association between positive affect and HRQOL. Methods: Participants, with premanifest (i.e., genetically at risk but no clinical diagnosis, n = 50) and manifest HD (earlystage n = 171; late-stage n = 101), completed a measure of positive affect and well-being and several HRQOL measures at baseline, 12-, and 24-month follow-ups. UHDRS Functional Assessment scale indicated functional status. Results: Positive affect was associated with better HRQOL for persons with premanifest and manifest HD over the 24-month time frame. These associations were moderated by functional status. For persons with higher functional status, positive affect was associated with better HRQOL, including less depression, lower anxiety, less anger, better social role satisfaction, better executive functions, greater upper extremity function, less dyscontrol, and less concern with death and dying. For persons with lower functional status, positive affect was not associated with HRQOL. Conclusions: Positive affect predicted better self-reported HRQOL over a 24-month period in persons with premanifest and manifest HD, particularly when participnats had better functional status. Interventions to enhance positive affect in HD may have beneficial effects on HRQOL.
UR - http://www.scopus.com/inward/record.url?scp=85065157223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065157223&partnerID=8YFLogxK
U2 - 10.3233/JHD-180341
DO - 10.3233/JHD-180341
M3 - Article
C2 - 31045519
AN - SCOPUS:85065157223
SN - 1879-6397
VL - 8
SP - 221
EP - 232
JO - Journal of Huntington's disease
JF - Journal of Huntington's disease
IS - 2
ER -